Cingulate Inc. Proceeds from Common Stock Issued
Cingulate Inc. (CING) reported Proceeds from Common Stock Issued of $31.05 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfCommonStock · last filed 2026-08-13
- Cingulate Inc. proceeds from issuance of common stock for the quarter ending 2026-06-30 was $9.14M, a 118.44% increase year-over-year.
- Cingulate Inc. proceeds from issuance of common stock for the quarter ending 2026-03-31 was $21.91M, a 1041.14% increase year-over-year.
- Cingulate Inc. proceeds from issuance of common stock for the quarter ending 2025-12-31 was $2.59M, a 73.76% increase year-over-year.
- Cingulate Inc. proceeds from issuance of common stock for the quarter ending 2025-09-30 was $1.46M, a 89.09% decline year-over-year.
- Cingulate Inc. proceeds from issuance of common stock for fiscal 2025 was $10.15M, a 60.76% decline from fiscal 2024.
- Cingulate Inc. proceeds from issuance of common stock for fiscal 2024 was $25.88M, a 271.19% increase from fiscal 2023.
- Cingulate Inc. proceeds from issuance of common stock for fiscal 2023 was $6.97M.
- Cingulate Inc. proceeds from issuance of common stock for fiscal 2021 was $20.37M.
| Period end | Proceeds from Issuance of Common Stock | Proceeds from Issuance of Common Stock 1 month | Proceeds from Issuance of Common Stock 3 month | Proceeds from Issuance of Common Stock 6 month | Proceeds from Issuance of Common Stock 9 month | Proceeds from Issuance of Common Stock 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $9.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $31.05M 10-Q · filed 2026-08-13 | $33.64M derived: sum of 3 quarters · filed 2026-08-13 | $35.10M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2026-03-31 | $21.91M 10-Q · filed 2026-05-14 | $24.50M derived: sum of 2 quarters · filed 2026-05-14 | $25.97M derived: sum of 3 quarters · filed 2026-05-14 | $30.15M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-12-31 | $2.59M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $4.05M derived: sum of 2 quarters · filed 2026-03-18 | $8.23M derived: sum of 3 quarters · filed 2026-08-13 | $10.15M 10-K · filed 2026-03-18 | ||
| 2025-09-30 | $1.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $5.65M derived: sum of 2 quarters · filed 2026-08-13 | $7.57M 10-Q · filed 2025-11-13 | $9.06M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-06-30 | $4.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $6.10M 10-Q · filed 2026-08-13 | $7.59M derived: sum of 3 quarters · filed 2026-08-13 | $21.00M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-03-31 | $1.92M 10-Q · filed 2026-05-14 | $3.41M derived: sum of 2 quarters · filed 2026-05-14 | $16.82M derived: sum of 3 quarters · filed 2026-05-14 | $17.90M derived: sum of 4 quarters · filed 2026-05-14 | ||
| 2024-12-31 | $1.49M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $14.90M derived: sum of 2 quarters · filed 2026-03-18 | $15.98M derived: sum of 3 quarters · filed 2026-03-18 | $25.88M 10-K · filed 2026-03-18 | ||
| 2024-09-30 | $13.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $14.49M derived: sum of 2 quarters · filed 2025-11-13 | $24.39M 10-Q · filed 2025-11-13 | $25.21M derived: sum of 4 quarters · filed 2025-11-13 | ||
| 2024-06-30 | $1.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-19 | $10.98M 10-Q · filed 2025-08-19 | $11.80M derived: sum of 3 quarters · filed 2025-08-19 | $17.73M derived: sum of 4 quarters · filed 2025-08-19 | ||
| 2024-03-31 | $9.89M 10-Q · filed 2025-05-08 | $10.71M derived: sum of 2 quarters · filed 2025-05-08 | $16.65M derived: sum of 3 quarters · filed 2025-05-08 | |||
| 2023-12-31 | $819.54K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $6.75M derived: sum of 2 quarters · filed 2025-03-27 | $6.97M 10-K · filed 2025-03-27 | |||
| 2023-09-30 | $3.30M 10-K · filed 2024-04-01 | $5.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $6.15M 10-Q · filed 2024-11-07 | |||
| 2023-08-11 | $3.30M 10-Q · filed 2023-11-13 | |||||
| 2023-06-30 | $218.80K 10-Q · filed 2024-08-13 | |||||
| 2021-12-31 | $20.37M 10-K · filed 2023-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |